IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Original HTML
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery, development and commercialization of targeted therapeutics, today announced that, on October 29, 2026, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 99,600 shares of the Company's common stock to four newly hired employees. The stock options were granted under the IDEAYA Biosciences, Inc. 2023 Employment Inducement Incentive Award Plan (2023 Inducement Plan) as an inducement material to such individuals' entering into employment with IDEAYA in accordance with Nasdaq Listing Rule 5635(c)(4).
The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of IDEAYA, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with IDEAYA, pursuant to Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of $32.89 per share, which is equal to the closing price of IDEAYA's common stock on The Nasdaq Global Select Market on the date of grant. The stock options have a 10-year term and will vest over four years, with 25% of the options vesting on the first anniversary of the vesting commencement date and the remaining 75% of the options vesting in equal monthly installments over the three years thereafter. Vesting of the stock options is subject to such employee's continued service to IDEAYA on each vesting date.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.
Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer
[email protected]
SOURCE IDEAYA Biosciences, Inc.
Share this article
Original Summary
<p>SOUTH SAN FRANCISCO, Calif., Oct. 30, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery, development and commercialization of targeted therapeutics, today announced that, on October 29, 2026, the Compensation...</p>
Generated Article_json
{"target_audience": "b2b", "is_medical": false, "ai_generated_title": "IDEAYA Grants 99,600 Inducement Options to Four New Hires", "body_html": "<p><strong>South San Francisco -- [CURRENT_DATE] --</strong> IDEAYA Biosciences (NASDAQ: IDYA) granted non-qualified stock options on an aggregate 99,600 shares of common stock to four newly hired employees, the precision oncology company disclosed. The Compensation Committee of its Board of Directors approved the awards on October 29, 2026.</p><h5>Options carry a $32.89 exercise price set at the grant-date close</h5><p>The strike price equals the closing price of IDEAYA stock on The Nasdaq Global Select Market on the grant date. At that price, the aggregate exercise value of the 99,600 shares comes to roughly $3.28 million, or an average of 24,900 shares per hire.</p><h5>Awards vest over four years with a 25% cliff after year one</h5><p>The options have a 10-year term. Twenty-five percent vest on the first anniversary of the vesting commencement date. The remaining 75% vest in equal monthly installments over the following three years. Each vesting date is conditional on the employee's continued service to IDEAYA.</p><h5>Grants fall under the 2023 Inducement Plan and Nasdaq Rule 5635(c)(4)</h5><p>IDEAYA issued the awards under its 2023 Employment Inducement Incentive Award Plan as an inducement material to each individual's decision to join the company. The plan is reserved exclusively for people who were not previously IDEAYA employees, or who return after a bona fide period of non-employment. It operates under Nasdaq Listing Rule 5635(c)(4).</p>", "meta_description": "IDEAYA Biosciences granted options on 99,600 shares to four new hires at a $32.89 exercise price, vesting over four years under Nasdaq's inducement rule.", "seo_keywords": "IDEAYA Biosciences, IDYA, inducement grants, stock options, Nasdaq Rule 5635(c)(4), precision oncology, employee equity awards, 2023 Inducement Plan", "companies": ["IDEAYA Biosciences"], "industries": ["Biopharmaceuticals"], "markets_regions": ["United States"], "news_type": ["financial_disclosure", "personnel_update"], "products": [], "themes": ["talent_acquisition", "executive_compensation"], "events": [], "cta_text": "Review IDEAYA Biosciences' investor disclosures for details on its 2023 Employment Inducement Incentive Award Plan", "learn_more": "", "fact_check": {"accuracy_score": 100, "legal_risk": "low", "corrections_made": ["Aggregate exercise value (~$3.28 million) and average per hire (24,900 shares) are derived from source figures: 99,600 x $32.89 and 99,600 / 4.", "Dateline uses the [CURRENT_DATE] placeholder per system rules."], "recommendation": "publish"}}
Content Hash (SHA-256, erste 32 hex)
2993d26f0a9ecf46760c54b79168e5be
